<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189917</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-007</org_study_id>
    <secondary_id>NIH N01-AI-30016</secondary_id>
    <nct_id>NCT00189917</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders</brief_title>
  <official_title>An Open-label, Controlled Phase I Pilot Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in 18-40 Year Old Vaccinia-naïve Subjects With Atopic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to gather information on the safety and immunogenicity of an
      investigational smallpox vaccine in populations with atopic disorders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence, relationship and intensity of any serious adverse event at any time during the study.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>ELISA specific seroconversion rates and geometric mean titres (at all blood sampling time points).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralisation assay specific seroconversion rates and geometric mean titres (at all blood sampling time points).</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <condition>Hay Fever</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE (MVA-BN)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects

          -  Age 18-40.

          -  Read, signed and dated informed consent.

          -  Women of childbearing potential must use an acceptable method of contraception

        Group 1: Healthy subjects

          -  No history of atopic dermatitis as documented in the patient file

          -  No active atopic dermatitis

          -  No other atopic disorders such as asthma or allergic rhinitis.

          -  Prick test without clinical significance

          -  IgE within normal range

        Group 2: Subjects with history of atopic dermatitis

        Group 3: Subjects with mild active atopic dermatitis

        - SCORAD 1 - 15.

        Group 4: Subjects with mild allergic rhinitis

          -  At least one active allergic rhinitis phase during last year.

        Exclusion Criteria:

          -  Known or suspected history of smallpox vaccination or typical vaccinia scar.

          -  Positive test result in MVA specific ELISA at screening.

          -  Positive result in HIV or HCV antibody test at screening.

          -  Surface antigen of Hepatitis B Virus (HBsAg) positive at screening.

          -  Pregnant or breast-feeding women.

          -  Positive pregnancy test at screening and/or within 24 hours prior to vaccination.

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above the
             institutional upper limit of normal.

          -  Positive urine glucose by dipstick or urine analysis.

          -  Inadequate renal function defined as a serum creatinine above the institutional upper
             limit of normal; urine protein &gt;30 mg/dl or trace proteinuria (by urine analysis or
             dipstick); and a calculated creatinine clearance &lt;80 ml/min.

          -  Electrocardiogram (ECG) with clinical significance.

          -  Hemoglobin &lt;11 g/dl; White blood cells less than 2,500 and more than 11,000/mm3;
             Platelets less than 140,000/mm3.

          -  Uncontrolled serious infection i.e. not responding to antimicrobial therapy.

          -  History of any serious medical condition, which in the opinion of the investigator
             would compromise the safety of the subject.

          -  History of or active autoimmune disease.

          -  Known or suspected impairment of immunologic function including, but not limited to,
             clinically significant liver disease; diabetes mellitus; moderate to severe kidney
             impairment.

          -  History of malignancy.

          -  History or clinical manifestation of clinically significant mental illness or
             haematological, renal, hepatic, pulmonary, central nervous, cardiovascular or
             gastrointestinal disorders.

          -  Any condition which might interfere with study objectives.

          -  History of immunodeficiency.

          -  History of myocardial infarction, angina, congestive heart failure, cardiomyopathy,
             stroke or transient ischemic attack, or other heart condition under the care of a
             doctor.

          -  Three or more of the following risk factors: High blood pressure, high blood
             cholesterol, diabetes mellitus or high blood sugar, a first degree relative who had a
             heart condition before the age of 50, smoking cigarettes.

          -  History of chronic alcohol abuse and/or intravenous drug abuse.

          -  History of allergic reactions likely to be exacerbated by any component of the
             vaccine.

          -  History of anaphylaxis or severe allergic reaction.

          -  Acute disease (illness with or without a fever) at the time of enrollment.

          -  Any vaccinations within a period starting 30 days prior to administration of the
             vaccine and ending at study conclusion.

          -  Chronic administration of immuno-suppressant or immune-modifying drugs.

          -  Post organ transplant subjects whether or not receiving chronic immunosuppressive
             therapy.

          -  Administration or planned administration of immunoglobulins and/or any blood -- Use of
             any investigational or non-registered drug.

          -  Blood donation 8 weeks in advance or during study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank von Sonnenburg, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases and Tropical Medicine of the University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Infectious Diseases and Tropical Medicine</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Roesch S, Baedeker N, Kollaritsch H, Chaplin P. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine. 2014 Sep 29;32(43):5696-702. doi: 10.1016/j.vaccine.2014.08.022. Epub 2014 Aug 20.</citation>
    <PMID>25149431</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2005</study_first_submitted>
  <study_first_submitted_qc>September 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Smallpox</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

